NCT05960032View on ClinicalTrials.gov

A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2023

Conditions
Healthy
Interventions
DRUG

Zavegepant

Participants receiving single dose of Zavegepant 10 mg

Trial Locations (1)

201107

Huashan Hospital,Fudan University, Shanghai

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05960032 - A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants | Biotech Hunter | Biotech Hunter